AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

19.80 0.35 +1.80%
Market cap
$6.8B
P/E
36.9×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a

AMNEAL PHARMACEUTICALS, INC. (AMRX) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, AMNEAL PHARMACEUTICALS, INC. (AMRX) trades at a EV/FCF of −158×. Over the past ten years it has ranged from −783× (September 2026) to 119× (August 2020); the current reading is higher than 9% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 27.3× 23.20%
FY2024 22.1× 70.17%
FY2023 13.0× (79.60%)
FY2022 63.8× 784.00%
FY2021 7.2× (29.56%)
FY2020 10.2× —
FY2019 −33.2× —
FY2018 23.5× 26.16%
FY2017 18.6× 0.00%
FY2016 18.6× 0.00%

Quarterly newest first

Period EV/FCF Change
Sep 2026 −162× —
Jun 2026 −695× —
Mar 2026 33.5× 22.84%
Dec 2025 27.3× 18.31%
43 more quarters

Against its own ten years

Low −783× High 119×
Ten-year median 19.4×
Current reading's percentile 9

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on AMRX